The Foundation will award a maximum of $100,000 annually, to seek out potential cures for cancer or to alleviate the impact of cancer.
Agencies may submit only one proposal per year.
The SAS Foundation accepts grant proposals annually. Proposals are due to the Foundation’s PO Box offices on Thursday, November 1st, 2018. Proposals postmarked but not received by this date cannot be considered. Early submission is recommended so that fulfillment of foundation guidelines can be met. Decisions will be announced approximately six to eight weeks after submission.
Please download and print the PDF below:
Summary of Grants Given
The Advisory Committee and Board have approved $50,000 Grants for the following:
To Roswell Park Alliance Foundation (Grantee) for MicroRNA expression profiling recurrence after resection of stage 1 Non-Small Cell Lung Cancer Project. Grant period for this award is December 18, 2009 through December 2011.
To Roswell Park Alliance Foundation (Grantee) for the identification of genes essential for mammary, pancreatic, epithelia, and melanocytes as potential targets for cancer therapy. The grant period for this award is December 3, 2010 through December 2012.
To Yale School of Medicine (Grantee) for the small molecule Magmas inhibitor (SMMI) pharmacokinests, and evaluation as a cancer treatment and imaging agent. The grant period for this award is November 23, 2011 through December 2013.
To Children's Hospital of Philadelphia (Grantee) for the "A Novel Approach to Enhance and redirect the anti-Leukemia Properties of human Invariant Natural Killer T cells", to develop new ways to stimulate the immune system to more effectively treat different types of cancer. The grant period for this award is November 9, 2012 through December 2014.
To Albert Einstein College of Medicine of Yeshiva University (Grantee) for the “Characterizing Magmas regulation and determining its role in energy metabolism and cancer treatment”. The grant period for this award is March 15, 2014 through December 2015.
To Roswell Park Alliance Foundation/Roswell Park Cancer Institute (Grantee) for the Inhibiting androgen deprivation therapy-induced sarcopenia in prostate cancer (prevention of castration-induced muscle loss in prostate cancer). The grant period for this award is November 25, 2015 through December 31, 2016.
To Albert Einstein College of Medicine (Grantee) for the Targeting the PRMT5 Arginine Methyltransferase: An Achilles’ Heel for Many Cancers. The grant period for this award is January 1, 2017 through December 31, 2017.
To University of Notre Dame (Grantee) for the Characterizing the role of Aquaporin-7 in the breast cancer metabolic landscape. The grant period for this award is January 1, 2017 through December 31, 2017.
To Roswell Park Alliance Foundation/Roswell Park Cancer Institute (Grantee) for the Prevention of prostate cancer progression and therapy-induced muscle loss. The grant period for this award is December 15, 2017 through December 31, 2018.